Non-Muscle Invasive Urothelial Carcinoma

Durvalumab Plus BCG May Improve Disease-Free Survival in Patients With NMIBC
Adding one year of treatment with durvalumab to BCG can extend the time that patients live without disease recurrence.
Advertisement

Latest News

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement